Introduction
============

Cerebral ischemia and its sequelae is one of the leading causes of death and long-term disability worldwide \[[@B1],[@B2]\]. In contrast to its common incidence, therapeutic options are limited. Due to the high vulnerability of neuronal tissue to oxygen deprivation, recanalization procedures have to take place in a limited time slot of 3 h and up to 4.5 h in special cases \[[@B1]\]. The area of greatest interest is the so called penumbra: the transition zone in between ischemic core and healthy tissue, where neurons are in a state of hibernation that can be restituted ad integrum with optimum treatment \[[@B3]\]. Numerous experimental therapeutic approaches have focused on protection and salvation of neurons in this area. While most of these therapeutics showed promising results in experimental studies, none to negative effects were seen in clinical trials \[[@B1]\]. Until today, and with limited recommendation, only therapeutic hypothermia has found its way into cerebral ischemia treatment guidelines \[[@B1],[@B2]\].

The noble gas argon has recently come into focus as a potential adjunctive neuroprotective agent: protective effects of noble gases have been widely shown in different experimental models \[[@B4]-[@B6]\], and argon seems to have similar beneficial effects on injured tissue \[[@B7]-[@B10]\]. Moreover, unlike xenon, it lacks sedative side effects under normobaric conditions \[[@B11]\], and is cheaper due to its higher fraction in normal atmosphere. These features plus expectedly little disadvantageous side effects in humans make argon a promising candidate. However, while neuroprotective effects of argon have already been demonstrated, data on its cellular actions are limited: *In vitro*, argon activated a cellular enzyme, and it only slightly interfered with the inflammatory microglial response following stimulation with bacterial lipopolysaccharide \[[@B12]\]. *In vivo,* an elevated expression of an anti-apoptotic protein was found elevated following argon treatment in neonatal asphyxia \[[@B7]\]. Argon's protective action was not exerted via NMDA-antagonism by interaction with glycine in a model of traumatic brain injury \[[@B9]\]. The mechanisms for argon's neuroprotective actions in cerebral ischemia are unknown.

The aim of this study was to shed first light on argon's mechanisms of action in a stroke model. 24 h after transient middle cerebral artery occlusion (tMCAO) \[[@B13]\] and a delayed additional administration of 50% argon as described previously \[[@B10]\], we performed a gene expression analysis of inflammatory and growth factors and examined the distribution of vital neurons, microglia and astrocytes in the penumbra.

Methods
=======

Study design and animal enrolment
---------------------------------

This experimental study was in part designed as a subgroup- and follow-up analysis of the above mentioned efficacy analysis of argon in MCAO \[[@B10]\], with additional enrolment of animals obtaining the same experimental procedures. Animal research and care procedures were approved by the governmental review board (Landesamt für Natur, Umwelt und Verbraucherschutz, Germany) beforehand. Species-appropriate housing was assured in macrolone cages in a specified pathogen-free environment, with food and water *ad libitum* and a 12 h-light-dark-cycle.

Transient middle cerebral artery occlusion (tMCAO)
--------------------------------------------------

Male Sprague Dawley rats (250-295 g, Harlan Laboratories, Netherlands) were randomly assigned to one of the following groups: a) sham surgery + placebo (Sham N~2~): n = 12; b) sham surgery + argon treatment (Sham Ar): n = 12; c) tMCAO + placebo (tMCAO N~2~): n = 15; and d) tMCAO + argon (tMCAO Ar): n = 15. One animal in the Sham Ar group was lost before completion of the 24 h follow-up due to other than intervention-associated reasons.

The interventional procedure is pictured in Figure [1](#F1){ref-type="fig"}A. Following induction of anaesthesia (0,15 mg/kg medetomidine, 2 mg/kg midazolam and 0.005 mg/kg fentanyl i.p.), animals underwent 2 h of tMCAO with the intraluminal thread-occlusion technique \[[@B10],[@B13]\] or sham surgery (identical surgical procedure without intraluminal thread-occlusion). Full occlusion of the middle cerebral artery (MCA) was assured by laser Doppler flowmetric assessment of the blood flow in this vessel (PeriFlux System 5000, Type PF 5001, Perimed, Sweden) as previously described \[[@B10]\]. Throughout the surgical procedure, animal body temperature was sustained at 37°C. Anaesthesia was maintained by repeated i.p. doses of 0.1-0.15 ml of the above described anesthetic mixture in 1 h intervals, if applicable titrated to clinical needs. Heart rate, arterial oxygen saturation and mean arterial blood pressure were continuously assessed, blood gases and pH were repeatedly measured to verify sufficient spontaneous breathing and circulation. At the end of the first hour after induction of tMCAO (or sham surgery), animals were treated according to their randomization with either placebo (nitrogen) or argon for another hour until reperfusion \[[@B10]\]. Argon or placebo were applied in an inspiratory concentration of 50% mixed with 50% oxygen via facial mask and spontaneous ventilation of the i.p. anesthetized animals. Sufficient ventilation was guaranteed by regular blood gas analyses for normoxia and normocarbia \[[@B10]\]. After 2 h of tMCAO including 1 h of treatment, reperfusion was restored by removal of the thread in the tMCAO animals. Following surgical closure of skin wounds and preemptive pain therapy (metamizole 15-50 mg/kg body weight), all animals were returned to their cages for recovery. Animals underwent neurological and behavioral testing \[[@B10],[@B14]\] directly before sacrifice at 24 h *post interventionem.*

![**Study procedure and exemplary histological graphics.** A simplified graphic of the study procedure is shown in **A**. After randomization animals received i.p. anesthesia and tMCAO or sham surgery. 1 h after the occlusion of the MCA with a thread treatment with 50% argon/50% oxygen or placebo (a 50% nitrogen/oxygen-mixture) was performed by mask inhalation for another hour. After that, treatment and MCA occlusion were terminated. Animals were left to recover from the procedure. 24 h later after behavioral testing, animals were sacrificed and brains obtained for further experiments. Example pictures of the HE-stained penumbra regions (slice 3) from the tMCAO + argon (MCAO Ar) and tMCAO + placebo (MCAO N~2~) groups vs. corresponding regions from sham + argon (Sham Ar) and sham + placebo (Sham N~2~) are shown in **B**. The demarcation zone between penumbra and necrotic tissue is tagged with a bold black line. The interhemispheric fissure is asterisked. The positions of the images taken for cell evaluation and quantification are marked by black rectangles (h healthy cortex; p penumbra; c ischemic core).](2045-9912-4-11-1){#F1}

Tissue preparation for gene expression analysis
-----------------------------------------------

Rat brains were removed immediately after sacrifice in deep anesthesia, cut into seven 2 mm thick coronal sections using a rat brain matrix (Plastics One Inc., USA) and stained at 37°C for 15 min in a 2% solution of 2,3,5-triphenyltetrazolium chloride (TTC) in normal saline to discriminate vital from dead tissue \[[@B15],[@B16]\]. Images of the TTC-stained sections were acquired (Sony DXC 390P, Sony Germany) before cryo-preservation at -80°C until further processing. Infarct volumes were assessed with an image analysis software (Optimas 6.5; Adept Electronic Solutions Pty Ltd, Sydney, Australia). Addition of all cross-sectional infarcted coronal brain sections which were multiplied by 2 (2 mm slice thickness) rendered the total infarct volumes of each infarcted brain \[[@B10]\]. Infarct volumes were edema-corrected by use of this formula \[[@B17]\]:

$$\mathit{Vedi} = \mathit{Vinfarct}*\left( 1 - \left( {\mathit{Vipsi} - \mathit{Vcontra}} \right)/\mathit{Vcontra} \right)$$

V edi = Volume edema-corrected infarct volume, V infarct = Volume infarct, V ipsi = Volume ipsilateral infarcted hemisphere, V contra = Volume contralateral non-infarcted hemisphere.

RNA isolation
-------------

On the basis of TTC-staining, the penumbra regions of the infarcted brain hemispheres were identified. Total RNA was isolated from the cortical penumbra of the infarcted hemisphere and corresponding contralateral regions from three consecutive coronal sections of each brain (sections 3, 4 and 5) employing NucleoSpin RNA II (MACHEREY-NAGEL, Germany) according to the manufacturers' instructions. Briefly, brain tissue was homogenized (5000 g, 15 s) with Precellys Keramik-Kit (PEQLAB Biotechnologie, Germany). Cells were further lysated with β-mercaptoethanol, filtrated by centrifugation and washed in 70% ethanol. DNA was digested and RNA purified in several washing steps and eluted in ultra-purified water (Invitrogen, Germany).

Gene expression analysis
------------------------

RNA concentrations and purity were measured using the NanoDrop1000 (PEQLAB Biotechnologie, Germany). Reverse transcription reactions were performed with M-MLV RT-kit (Invitrogen, Germany) according to the manufacturer's instructions and random hexanucleotide primers (Invitrogen, Germany). Real-time rtPCR (RT-rtPCR) reactions were carried out in a mixture containing 2 μl cDNA, 2 μl RNAse-free water (Invitrogen, Germany), 5 μl 2 × Sensi Mix × Plus SYBR & Fluorescein Kit (Quantace, Bioline, Germany) and 0.5 μl primers (10pmol/μl). Primer sequences are listed in Table [1](#T1){ref-type="table"}. Reactions were conducted in standard tubes using the MyiQ RTrtPCR detection system (Bio-Rad Laboratories, Germany) under the following conditions: 10 min enzyme activation at 95°C, 40 times 15 s denaturation at 95°C then 30 s annealing at individual temperatures then 30 s amplification at 72°C, and 5 s fluorescence measurement at 72°C. Internal standard curves to assess the concentration of the target gene in the samples were generated by measuring several dilutions of a target gene pool with each reaction. Melting curve analysis and agarose gel electrophoretic evaluation of the RT-rtPCR products were routinely performed to determine the specificity of the RT-rtPCR reaction. Gene expressions were normalized to the mean expression values of the housekeeping gene cyclophilin A; the expression levels of the infarcted hemispheres were furthermore set in relation to their corresponding contralateral hemispheres.

###### 

Primer sequence, product length and characteristics

  **Transcript**                                      **Sequence**                 **Orientation**   **Annealing temperature (°C)**   **Transcript size (base pairs)**   **Melting point (°C)**   **GeneBank_ID**
  --------------------------------------------------- ---------------------------- ----------------- -------------------------------- ---------------------------------- ------------------------ -----------------
  Cyclophilin                                         GGCAAATGCTGGACCAAACAC        Sense             60                               196                                82                       NM_017101.1
                                                      TTAGAGTTGTCCACAGTCGGAGATG    Antisense                                                                                                      
  Tumor nekrose faktor alpha                          CTCCCAGAAAAGCAAGCAACC        Sense             57                               210                                85                       NM_012675.3
  (TNFα)                                              CGAGCAGGAATGAGAAGAGG         Antisense                                                                                                      
  Interleukin-1β                                      CTGTGACTCGTGGGATGATG         Sense             60                               210                                81                       NM_031512.2
  (IL-1β)                                             GGGATTTTGTCGTTGCTTGT         Antisense                                                                                                      
  Interleukin-6                                       CCGGAGAGGAGACCTCACAG         Sense             60                               161                                78                       NM_012589.1
  (IL-6)                                              ACAGTGCATCATCGCTGTTC         Antisense                                                                                                      
  Chemokine (C-C) ligand 2                            CCAGAAACCAGCCAACTCTC         Sense             59                               192                                83                       NM_031530.1
  CCL2                                                CCGACTCATTGGGATCATCT         Antisense                                                                                                      
  Matrix metalloproteinase-9                          CCACCGAGCTATCCACTCAT         Sense             60                               180                                79                       NM_031055.1
  MMP-9                                               GTCCGGTTTCAGCATGTTTT         Antisense                                                                                                      
  Hypoxia inducible factor 1                          TCAAGTCAGCAACGTGGAAG         Sense             60                               198                                81                       NM_024359.1
  alpha (HIF-1α)                                      TATCGAGGCTGTGTCGACTG         Antisense                                                                                                      
  Chemokine (C-C) ligand 5                            TGCCCACGTGAAGGAGTATTTTTA     Sense             60                               81                                 78                       NM_031116.3
  (CCL5)                                              TGGCGGTTCCTTCGAGTGACAA       Antisense                                                                                                      
  Transforming growth factor β (TGF-β)                GGGACTCTCCACCTGCAAGAC        Sense             63                               393                                88                       NM_012578.2
  CTCTGCAGGCGCAGCTCTG                                 Antisense                                                                                                                                   
  Nerve growth factor                                 GAAACGGAGACTCCGTTCACC        Sense             60                               100                                82                       NM_001067130.1
  (NGF)                                               GATTGTACCATGGGCCTGGA         Antisense                                                                                                      
  Vascular endothelial growth factor α (VEGFα)        CCTGGTGGACATCTTCCAGGAGTACC   Sense             60                               196                                84                       NM_031836.2
  GAAGCTCATCTCTCCTATGTGCT                             Antisense                                                                                                                                   
  Inducible NO-synthetase                             CACCTTGGAGTTCACCCAGT         Sense             59                               179                                85                       NM_012611.3
  (iNOS)                                              ACCACTCGTACTTGGGATGC         Antisense                                                                                                      
  CD3                                                 AGAACTGCATGGAGGTGGAC         Sense             60                               232                                84                       NM_001108140.1
                                                      TTTCGGATGGGCTCATAGTC         Antisense                                                                                                      
  CD11b                                               TTACCGGACTGTGTGGACAA         Sense             62                               219                                82                       NM_012711.1
                                                      AGTCTCCCACCACCAAAGTG         Antisense                                                                                                      
  2'3'-Cyclic nucleotide 3' phosphodiesterase (CNP)   TGGCGAAGAAGATGGAAGTCA        Sense             60                               257                                82                       M18630.1
  GTGGGTGAAGGAACTGATGGTT                              Antisense                                                                                                                                   
  Glial fibrillary acid protein                       AGAAAACCGCATCACCATT          Sense             60                               188                                83                       NM_017009.2
  (GFAP)                                              GCACACCTCACATCACATCC         Antisense                                                                                                      
  Insulin-like growth factor 1                        TGATCTGAGGAGGCTGGAGATGTA     Sense             59                               95                                 82                       NM_178866.4
  IGF-1                                               CTTCTGAGTCTTGGGCATGTCA       Antisense                                                                                                      

A full summary of the primer sequences employed for gene expression analysis plus their characteristics is given in Table [1](#T1){ref-type="table"}.

The primer sequences and further information about the transcripts we analyzed is given in Table [1](#T1){ref-type="table"}. We selected the transcripts for analysis as follows: Argon was found to have effects on both glial and neuronal cells, and it only slightly attenuated LPS-induced production of cytokines IL-1β, TNFα and IL-6 in a microgial cell line \[[@B12]\]. HIF-1α was found to be induced in xenon but not in argon renal cell protection \[[@B18]\]. Since knowledge about argon effects is in general very limited, additional factors that are released by neuronal or glial or invading immune cells and are furthermore associated with damage and/or repair following neurotrauma were chosen for analysis.

Immunhistochemistry (IHC)
-------------------------

In deep anesthesia, rats were transcardially perfused with 2% (w/v) paraformaldehyde (Roth, Germany) containing 15% (v/v) saturated picric acid at pH 7.4 (AppliedChem, Germany). Brains were removed, kept in the same fixative overnight and paraffin-embedded the next day (Merck, Germany). Coronary sections (slices 3 and 5) of 5 μm thickness were prepared, mounted on glass slides and rehydrated using standard protocols. To verify infarction (MCAO) or integrity (Sham), sections were stained with hematoxylin/eosin (HE) using a standard protocol (Exemplary pictures are presented in Figure [1](#F1){ref-type="fig"}B). For IHC, sections were incubated with blocking serum for 1 h at room temperature, following exposure to primary antibodies overnight (anti-NeuN (1:500, Abcam, Cambridge, UK), anti-GFAP (1:1000, Abcam, Cambridge, UK), and anti-ionized calcium-binding adaptor molecule 1 (Iba1, 1:250, Wako, Osaka, Japan). After several washing steps, sections were incubated with biotin-conjugated secondary antibody for 1 h, and subsequently with a biotin--avidin--enzyme complex (Vectastain ABC kit, Vector Laboratories, Burlingame, USA). Antibody binding was visualized by substrate incubation (AEC Substrate kit, Invitrogen, Camarillo, USA). To quantify vital cells, standard light microscopy with a 20× objective lens was performed and images were taken of three defined regions (healthy cortex, cortex penumbra and ischemic core, see Figure [1](#F1){ref-type="fig"}B) in the infarcted hemisphere and of corresponding contralateral regions with a standard digital camera. Vital neurons (NeuN positive cells with a vital large light caryon without shrinked/dense apperance), astrocytes (GFAP-positive cells with minimum three branches) and microglia (Iba1-positive cells with minimum two rami) were analyzed with the help of a cell count software (ImageJ, <http://rsbweb.nih.gov/ij/>) by two independent examiners blinded to the treatment.

Statistics
----------

Parametric data were evaluated by oneway ANOVA, followed by post-hoc Newman-Keuls-testing for statistical significance. GraphPad PRISM (GraphPad Software Inc., La Jolla, California, USA) was used to calculate the statistics and generate the figures. All values are given as means ± SEM. A p-value ≤ 0.05 was considered statistically significant.

Results
=======

Expression of inflammatory genes
--------------------------------

Expression of the cell marker protein CD3 was significantly higher in the penumbra of tMCAO + placebo animals compared to tMCAO + argon or sham (Figure [2](#F2){ref-type="fig"}A). Chemokine CCL2-expression levels were significantly elevated in both tMCAO (+argon/+placebo) groups in comparison to sham, with no significant difference between tMCAO groups (Figure [2](#F2){ref-type="fig"}C). Interleukines' IL-1β and IL-6 expression was significantly elevated in the penumbra of the tMCAO + argon group compared to tMCAO + placebo (IL-1β: 1.7 fold increase of induction, p \< 0.05; IL-6: 1.7 fold increase of induction, p \< 0.05; Figure [2](#F2){ref-type="fig"}F, [3](#F3){ref-type="fig"}A). IL-1β and IL-6 expression was significantly elevated in tMCAO + argon but not in tMCAO + placebo penumbra compared to the sham animals (Figure [2](#F2){ref-type="fig"}F, [3](#F3){ref-type="fig"}A). The same was found for iNOS expression, which was significantly induced in the penumbra of the tMCAO + argon group (3.5 fold increase of induction compared to tMCAO + placebo, p \< 0.001), but not in the penumbra of the tMCAO + placebo group (Figure [3](#F3){ref-type="fig"}C) compared to the sham animals. CD11b, CCL5 and TNFα expression levels were not significantly elevated at 24 h following cerebral infarction compared to healthy controls (Figures [2](#F2){ref-type="fig"}, B, D, E). The expression of matrix metalloproteinase-9 (MMP-9) and hypoxia inducible factor (HIF)-1α were significantly higher in the penumbra following cerebral ischemia compared to healthy controls, with no significant difference between tMCAO + argon and tMCAO + placebo (Figures [3](#F3){ref-type="fig"}B, D).

![**Expression levels of inflammatory genes.** Expression levels of different inflammatory genes measured by RT-PCR are shown in Figure [2](#F2){ref-type="fig"} (**A**: CD3; **B**: CD 11b; **C**: CCL2; **D**: CCL5; **E**: TNFα; **F**: IL-1β). Samples were taken from the penumbra in tMCAO or corresponding region in sham animals plus corresponding contralateral regions (Sham N~2~ n = 9; Sham Ar n = 8; tMCAO N~2~ n = 12; tMCAO n = 12). All values are presented as mean ± SEM. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](2045-9912-4-11-2){#F2}

![**Expression levels of further factors involved in post-ischemic inflammation and repair.** Expression levels of different factors involved in post-ischemic inflammation and repair processes measured by RT-PCR are shown in Figure [3](#F3){ref-type="fig"} (**A**: IL-6; **B**: HIF-1α; **C**: iNOS; **D**: MMP9). Samples were taken from the penumbra in tMCAO or corresponding region in sham animals plus corresponding contralateral regions (Sham N~2~ n = 9; Sham Ar n = 8; tMCAO N~2~ n = 12; tMCAO n = 12). All values are presented as mean ± SEM. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](2045-9912-4-11-3){#F3}

Expression of growth factors
----------------------------

The expression levels of 2\',3\'-cyclic-nucleotide 3\'-phosphodiesterase (CNP), glial fibrillary acid protein (GFAP), and insulin-like growth factor (IGF)-1 were not affected 24 h after the intervention in the different study groups (Figures [4](#F4){ref-type="fig"}A, B, F). A significant upregulation of transforming growth factor (TGF)-β, and neuronal growth factor (NGF) mRNA-levels was found in the penumbra 24 h following tMCAO + argon treatment compared with tMCAO + placebo (TGF-β: 1.7 fold increase of induction, p \< 0.01; NGF: 1.5 fold increase of induction, p \< 0.05; Figures [4](#F4){ref-type="fig"}C, E). TGF-β and NGF expression was found significantly elevated in tMCAO + argon but not in tMCAO + placebo penumbra when compared to sham (Figures [4](#F4){ref-type="fig"}C, E). Argon treatment following tMCAO further led to a significantly increased expression of vascular endothelial growth factor (VEGF)α in the penumbra compared to sham, but not to tMCAO + placebo (Figure [4](#F4){ref-type="fig"}D).

![**Expression levels of repair and growth factors.** Expression levels of different growth factor genes involved in cerebral cell differentiation and measured by RT-PCR are shown in Figure [4](#F4){ref-type="fig"} (**A**: CNP; **B**: GFAP; **C**: NGFb; **D**: VEGF; **E**: TGF β; **F**: IGF-1). Samples were taken from the penumbra in tMCAO or corresponding region in sham animals plus corresponding contralateral regions (Sham N~2~ n = 9; Sham Ar n = 8; tMCAO N~2~ n = 12; tMCAO n = 12). All values are presented as mean ± SEM. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](2045-9912-4-11-4){#F4}

Distribution of neurons, microglia, and astrocytes
--------------------------------------------------

### Neu-N staining

24 h following tMCAO versus sham surgery, numbers of vital neurons in the healthy contralateral hemispheres were comparable in all study groups (data not shown). In the ischemic core of the infarcted hemispheres, vital neurons were significantly reduced following tMCAO + placebo (Figure [5](#F5){ref-type="fig"}A) when compared to healthy ipsilateral regions or healthy tMCAO + argon. No significant differences were found between tMCAO + argon healthy and ischemic tissue, or between tMCAO + placebo and tMCAO + argon penumbra or ischemic core (Figure [5](#F5){ref-type="fig"}A). Example stainings are shown in Figure [6](#F6){ref-type="fig"}A.

![**Cell numbers of neurons, astrocytes and microglia in healthy cortex, penumbra and ischemic core region.** The numbers of neurons **(A)**, microglia **(B)** and astrocytes **(C)** differentiated by immunohistochemical staining in healthy ipsilateral cortex (healthy), penumbra (penumbra) and ischemic core (ischemia) of tMCAO animals and their corresponding sham regions are shown in Figure [5](#F5){ref-type="fig"}. (Sham N~2~ n = 3; Sham Ar n = 3; tMCAO N~2~ n = 3; tMCAO n = 3). All values are presented as mean ± SEM. \* p \< 0.05.](2045-9912-4-11-5){#F5}

![**Immunhistochemical stainings of neurons, astrocytes and microglia in healthy cortex, penumbra and ischemic core region.** Example pictures of neurons (NeuN staining, **A)**, microglia (Iba-1 staining, **B)** and astrocytes (GFAP staining **C)** taken from healthy ipsilateral cortex (h), penumbra (p) and ischemic core (c) of tMCAO animals and their corresponding sham regions are shown in Figure [6](#F6){ref-type="fig"}. (Sham N~2~ n = 3; Sham Ar n = 3; tMCAO N~2~ n = 3; tMCAO n = 3).](2045-9912-4-11-6){#F6}

### Iba-1 staining

Microglia counts were comparable in healthy contralateral hemispheres in all study groups (data not shown). Microglia numbers were not significantly different among treatment groups neither in the ischemic nor in the penumbra or healthy region (Figure [5](#F5){ref-type="fig"}B). Example stainings are shown in Figure [6](#F6){ref-type="fig"}B.

### GFAP-staining

Astrocyte numbers were not significantly different among treatment groups neither in the ischemic (Figure [5](#F5){ref-type="fig"}C) nor in the contralateral hemispheres (data not shown). Example stainings are shown in Figure [6](#F6){ref-type="fig"}C.

Discussion
==========

Recent experimental studies were able to demonstrate neuroprotective properties of argon in different ischemic and traumatic settings \[[@B6]-[@B10],[@B19]\]. However, cellular and molecular processes leading to this neuroprotection are largely unknown. With this study, we intended to start elucidating protective mechanisms of argon treatment in a model of transient focal cerebral ischemia in rats. We identified several genes whose transcription was elevated 24 h after intervention, and whose expression levels significantly differed between argon treatment and placebo following tMCAO. Apart from the ischemic core in tMCAO + placebo animals, numbers of astrocytes, microglia and neurons were not significantly different in the study groups.

Following tMCAO + argon, several inflammatory markers showed significantly higher expression levels in the argon group at 24 h post interventionem. The cytokines IL-1β and IL-6 are regularly secreted by neurons and glia in response to an ischemic stimulus and are involved in macrophage attraction and binding \[[@B20]\]. Especially IL-1β is actively produced and released in stroke in tattered neurons and activated microglia by activation of inflammasomes and apoptotic pathways in the hypoxic brain. These differences in gene expression seem contradictory to the neuroprotective effects exerted by argon in tMCAO in rats \[[@B10]\]. The cytokines have mostly been found to aggravate tissue damage in ischemia \[[@B20]-[@B22]\]. IL-6 has also been attributed a protective role \[[@B23],[@B24]\]. About both the underlying pathomechanisms and the prospects of these unexpected results we may only speculate. Direct as well as subordinate effects of argon on the injured tissue might be underlying these findings. Of note, expression kinetics of these cytokines showed an immediate up-regulation approximately one to two hours after brain injury induction with peak levels after 6 to 12 h \[[@B25],[@B26]\]. Since in our study mRNA levels were measured with a delay of 24 h after reperfusion, it might be thinkable that besides a prolonged upregulation of these cytokines, argon might induce a delay of mRNA-expression which might effect a shift of peak expression to a later time point. At 24 h post-ischemia the elevated expression of iNOS, whose role in ischemic brain damage and repair is still discussed \[[@B27],[@B28]\], might also be due to altered cytokine kinetics. Another important point to consider is that the timing of sampling might contribute to these confusing results. Only having the 24-hour snap shot might not be sufficient to draw mechanistic conclusions. Both earlier (first 6-to-12 hours of post-ischemia) and later (48 hours post-ischemia) sampling will have to be evaluated in further studies to examine these seemingly controversial results and their link to tissue protection.

Growth factors are involved in initiation of repair mechanisms to organize tissue damage and initiate cell migration and differentiation. TGF-β-expression was found to be elevated 24 h after tMCAO + argon while it was not affected by tMCAO + placebo. TGF-β is associated with profound neuroprotective activities \[[@B29],[@B30]\]. NGF, which was also induced by argon treatment in our study, has been shown to exert neuroprotective properties partly via an antiapoptotic mechanism \[[@B31]\]. VEGFα plays a role in regulation of cerebral blood flow and angiogenesis and thereby is proposed to act as a neuroprotectant \[[@B32]\]. The fact that these neuroprotective factors were increased following argon therapy might contribute to its beneficial effects \[[@B10]\].

Tissue protection by xenon preconditioning and treatment has been associated with an up-regulation of HIF-1α in several *in vivo* and *in vitro* models of ischemia \[[@B18],[@B33],[@B34]\]. Argon preconditioning did not induce HIF-1α in renal ischemia *in vitro*, but also lacked protective effects in this experiment \[[@B18]\]. In our study, we did not find an upregulated expression of HIF-1α following argon treatment of tMCAO induced cerebral ischemia despite of it's neuroprotective effects \[[@B10]\]. Whether the missing induction of HIF-1α is specific to argon, or due to other reasons (timing of treatment, examination time) will have to be determined elsewhere.

Still, some open questions remain: There was no statistically significant difference in neuron numbers between tMCAO + argon and tMCAO + placebo in the penumbra, although behavioural scoring and cortical infarct volumes in tMCAO + argon animals had been improved compared to placebo treatment \[[@B10]\]. A higher number of animals might be required to establish such a correlation. Alternatively, the reason for this finding could be that the behavioural scoring does not reflect the neuronal situation in the penumbra. Furthermore, we found several notable changes in the expression of the above named genes, but their exact cellular source remains to be identified. Additional studies will have to address these questions.

Conclusion
==========

In our study, we found controversial results. Besides elevated expressions of several inflammatory cytokines (IL-1β, IL-6, iNOS) we found an increased expression of neuroprotective growth factors (TGFβ, NGF, VEGF) following tMCAO + argon compared to tMCAO + placebo. These findings might be associated with the previously described neuroprotective effects of argon following experimental neurotrauma. Further studies will have to evaluate the relevance of these findings.
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